Abstract
A 36-year-old transgender man (assigned female at birth) on exogenous testosterone therapy was found to have stage IIA ovarian endometrioid carcinoma, and underwent adjuvant chemotherapy. Diffuse androgen receptor expression in the tumor initiated a multidisciplinary discussion regarding the safety of continuing exogenous testosterone as gender-affirming hormone therapy.
Copyright © 2021 Elsevier Inc. All rights reserved.
MeSH terms
-
Adult
-
Androgens / adverse effects*
-
Androgens / therapeutic use
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Biomarkers, Tumor / metabolism*
-
Carboplatin / therapeutic use
-
Carcinoma, Endometrioid / chemically induced*
-
Carcinoma, Endometrioid / diagnosis
-
Carcinoma, Endometrioid / metabolism
-
Carcinoma, Endometrioid / therapy
-
Chemotherapy, Adjuvant
-
Female
-
Gender-Affirming Procedures / adverse effects*
-
Gender-Affirming Procedures / methods
-
Humans
-
Male
-
Ovarian Neoplasms / chemically induced*
-
Ovarian Neoplasms / diagnosis
-
Ovarian Neoplasms / metabolism
-
Ovarian Neoplasms / therapy
-
Paclitaxel / therapeutic use
-
Receptors, Androgen / metabolism*
-
Salpingo-oophorectomy
-
Testosterone / adverse effects*
-
Testosterone / therapeutic use
-
Transgender Persons
Substances
-
AR protein, human
-
Androgens
-
Antineoplastic Agents
-
Biomarkers, Tumor
-
Receptors, Androgen
-
Testosterone
-
Carboplatin
-
Paclitaxel